Deep Venous Thrombosis Clinical Trial
Official title:
Identification of the Optimal Approach to the Ultrasound Diagnosis of Deep Vein Thrombosis of the Lower Extremities in Symptomatic Patients
Prospective cohort study aimed at simplifying the diagnostic approach to symptomatic patients with the clinical suspicion of deep vein thrombosis (DVT) of the lower extremities. All patients will receive a pre-test clinical probability (PTP) and the determination of D-dimer. Patients with low PTP and negative D-dimer will have the diagnosis ruled out. All other patients will undergo compression ultrasonography (CUS) of the proximal vein system. Patients with negative CUS and either low PTP or negative D-dimer will have the diagnosis ruled out, while those with high PTP and positive D-dimer will undergo extensive ultrasound investigation of the calf vein system. All patients in whom the diagnosis of DVT is ruled out will be followed-up prospectively up to three months for documenting the development of symptomatic thromboembolic events.
All eligible patients will undergo D-dimer measurement and a formal assessment of pre-test
clinical probability (PTP) by means of the Wells score. Patients with unlikely PTP and
negative D-dimer will have DVT ruled out and will undergo a 3-month clinical follow-up. If
at least one of the two tests is positive, patients will undergo CUS of the proximal vein
system by investigating at least the common femoral vein at the groin, the superficial
femoral vein at the mid thigh and the popliteal vein(s) in the popliteal fossa. A positive
CUS will adjudicate proximal DVT. In the case of negative CUS of the proximal vein system,
patients with either negative D-dimer or unlikely PTP will have DVT ruled out, and will
undergo a 3-month follow up. Only patients with concomitant likely PTP and positive D-dimer
will undergo whole-leg ultrasonography with interrogation of the calf veins. A positive test
will adjudicate distal DVT. Patients with negative test will undergo a 3-month clinical
follow up.
Follow-up. All patients in whom DVT is ruled out will be monitored for 3 months (either by
clinical visit or by telephone contact) after the enrolment in the study. Patients with
clinical symptoms of DVT or PE during follow-up will undergo objective diagnostic testing
(venous ultrasound for suspected DVT and spiral CT-scan or VQ scan for suspected PE). All
source documents will be sent out for an independent adjudication. In case of death, PE
diagnosis will be adjudicated by means of autopsy, if available. If autopsy is not
available, the adjudication of PE-related death will be done based on clinical
documentation.
D-dimer. All quantitative D-dimer tests available at each center will be acceptable for the
purpose of this study. D-dimer will be considered negative according to the cut-offs
provided by manufacturers.
Sample size. The investigators expect that in every 100 symptomatic outpatients DVT will be
excluded without the need for objective testing in approximately 30%, while approximately
20% will have a CUS-detected proximal DVT, approximately 15% will have negative CUS and
unlikely PTP in spite of positive D-Dimer (no need for further investigation), approximately
15% will have negative CUS and negative D-Dimer in spite of likely PTP (no need for further
investigation, and approximately 20% will have negative CUS and both likely PTP and positive
D-Dimer (thus requiring interrogation of the calf vein system).
The investigators hypothesize that the incidence of venous thromboembolic events during
follow up in patients labeled as not having DVT will not exceed 1% with the application of
the proposed algorithm, and that the upper limit of the 95% confidence intervals around this
proportion will not exceed 2%. Accordingly, ap proximately 1100 patients should be enroled.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT02889562 -
Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
|
Phase 2/Phase 3 | |
Completed |
NCT00812370 -
The UNBLOCK Study: Utilization of Bivalirudin On Clots in Kids
|
Phase 1 | |
Completed |
NCT01333618 -
Introducer Curving Technique for Tilt of Transfemoral Günther Tulip Inferior Vena Cava Filter
|
N/A | |
Completed |
NCT02552420 -
The Clinical Application of Infrared Thermal Imaging Detecting Venous Thromboembolism
|
Phase 2/Phase 3 | |
Completed |
NCT00178789 -
Sonography Outcomes Assessment Program for Lower Extremity Deep Venous Thrombosis
|
Phase 1/Phase 2 | |
Completed |
NCT03251963 -
Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients
|
Phase 2 | |
Completed |
NCT03286985 -
The Prevalence and Incidence of DVT in General ICU
|
||
Completed |
NCT04414332 -
Registry of Angiovac Procedures In Detail Outcomes Database-RAPID Registry
|
||
Completed |
NCT02211326 -
Genotype-guided Warfarin Individualized Treatment
|
N/A | |
Completed |
NCT03296280 -
Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program
|
||
Recruiting |
NCT03937583 -
Screening for Cancer in Patients With Unprovoked VTE
|
Phase 4 | |
Completed |
NCT00628576 -
Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities
|
Phase 3 | |
Completed |
NCT04979026 -
Clinical Investigation of a Novel Approach for the Prevention of Deep Venous Thrombosis After Total Knee Replacement
|
N/A | |
Active, not recruiting |
NCT02318472 -
Early Mobilization After Achilles Tendon Rupture
|
N/A | |
Completed |
NCT01221805 -
STA®-Liatest®D-Di-Exclusion of Venous Thromboembolism
|
Phase 4 | |
Recruiting |
NCT03740633 -
Functional Training for the Prevention of Deep Venous Thrombosis
|
Phase 3 | |
Completed |
NCT03707665 -
Deep Venous Thrombosis Screening in the ICU by Nurses
|
||
Recruiting |
NCT05171049 -
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
|
Phase 3 | |
Completed |
NCT01542723 -
Pot-Kast: Thrombosis Prophylaxis After Knee Arthroscopy
|
N/A |